Taiwan Biotechs Look To Meet China’s Appetite For NCEs Despite Challenges
This article was originally published in PharmAsia News
Executive Summary
Taiwanese biotechs are initiating late-stage studies of compounds in mainland China to expedite NDA filings. Frontrunners are edging closer to the finish line despite mounting challenges.